RBOT Stock Risk & Deep Value Analysis
Vicarious Surgical Inc
DVR Score
out of 10
What You Need to Know About RBOT Stock
We analyzed Vicarious Surgical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RBOT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RBOT Risk Analysis & Red Flags
What Could Go Wrong
The company faces an imminent liquidity crisis, with its cash runway projected to end by Q2 2026 (June 30, 2026). Without securing substantial new financing immediately, which could be highly dilutive to existing shareholders, the company risks inability to fund ongoing operations, further R&D, or even remain a going concern, leading to potential bankruptcy or asset liquidation.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Delisted from NYSE to OTC in early March 2026, severely impacting market visibility and liquidity.
- ⚠
Projected cash runway only through Q2 2026 (as of March 2026), indicating immediate need for capital without confirmed funding in the provided real-time intelligence.
- ⚠
Planned reverse stock split for Nasdaq relisting, often viewed negatively by investors and can be a sign of desperation.
- ⚠
History of missing strategic timelines and unsustainable financial trajectory.
Upcoming Risk Events
- 📅
Failure to secure additional financing by end of Q2 FY2026 (June 30, 2026): Leads to imminent liquidity crisis, potential bankruptcy, or forced asset sale at distressed prices.
- 📅
Failure to achieve Nasdaq relisting (Q3 FY2026): Prolongs OTC status, hindering access to capital markets and maintaining low liquidity and investor interest.
When to Reconsider
- 🚪
Exit if no clear financing update or extension of cash runway is announced by the end of Q2 FY2026 (June 30, 2026).
- 🚪
Sell if management announces further significant delays to Nasdaq relisting or clinical trial milestones.
- 🚪
Liquidate position if further major share dilution (e.g., >50% ownership transferred to new investors) is announced without clear path to profitability.
Unlock RBOT Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Vicarious Surgical successfully secures a substantial capital infusion (e.g., $50M+) in Q2/Q3 2026 and re-lists on Nasdaq, then it could regain some investor confidence and extend its cash runway to fund critical clinical trials, potentially re-rating its minimal valuation from current distressed levels. This is bullish because the underlying robotic technology for minimally invasive surgery holds unique potential, which is currently overshadowed by immediate financial collapse risk.
Is RBOT Stock Undervalued?
Unlock the full AI analysis for RBOT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RBOT Price Targets & Strategy
12-Month Target
$0.10
Bull Case
$0.75
Bear Case
$0.01
Valuation Basis
Based on severe financial distress and high probability of further dilution/restructuring, targeting a nominal value; potential upside assumes successful, highly dilutive financing and Nasdaq relisting.
Entry Strategy
Avoid direct investment; extremely speculative. If considering, wait for clear evidence of successful funding and Nasdaq relisting. No reliable technical levels due to OTC status and price volatility.
Exit Strategy
For current shareholders, any significant positive news (e.g., confirmed funding) that causes a price spike should be considered an exit point. Stop loss effectively at current levels given high risk of total loss.
Portfolio Allocation
0% for conservative, 0% for moderate, <0.1% for highly aggressive (speculative 'lottery ticket' money only, with full understanding of potential total loss).
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is RBOT Financially Healthy?
Profitability
Return on Equity
-333.19%
Revenue Growth
-64.63%
EPS
$-6.68
Balance Sheet
Current Ratio
2.97
Quick Ratio
2.51
Debt/Equity
0.05
Other
Beta (Volatility)
1.89
Does RBOT Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
While the company has patented technology, its financial distress and inability to commercialize erode any potential moat. Without significant capital, the IP itself is at risk of becoming a distressed asset or being acquired cheaply by competitors, thereby failing to create a sustainable competitive advantage.
Moat Erosion Risks
- •Inability to secure sufficient funding to complete clinical trials and achieve commercialization, allowing competitors to catch up or acquire technology.
- •Failure to achieve FDA clearance for its robotic platform, rendering its core IP commercially unviable.
RBOT Competitive Moat Analysis
Sign up to see competitive advantages
RBOT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (Due to delisting, low share price, and high risk of dilution/bankruptcy, retail sentiment is likely negative and speculative.)
Institutional Sentiment
Negative (Lack of institutional coverage post-delisting, previous analyst sentiment likely negative given financial state. No new analyst data in provided research.)
Insider Activity (Form 4)
No specific insider Form 4 filings or aggregated activity were provided in the real-time market intelligence. Historically, management has been focused on securing funding.
Options Flow
Normal options activity (Given OTC status, options trading is likely very limited or non-existent, making 'normal' a placeholder for lack of specific data.)
Earnings Intelligence
Next Earnings
Estimated late May 2026 for Q1 FY2026 (for quarter ended March 31, 2026), but not provided in current intelligence. Likely already missed or imminent if not yet reported.
Surprise Probability
Medium (Highly dependent on cash burn and any unannounced financing; difficult to predict given severe financial constraints.)
Historical Earnings Pattern
Likely volatile reactions to earnings, heavily swayed by liquidity updates and strategic financing announcements, rather than operational results.
Key Metrics to Watch
Competitive Position
Top Competitor
Intuitive Surgical (ISRG)
Market Share Trend
Not applicable as the company is pre-commercialization and focused on survival.
Valuation vs Peers
Trading at a massive discount (implied negligible valuation) due to severe financial distress, pre-revenue status, and liquidity issues, making direct comparable valuation metrics irrelevant.
Competitive Advantages
- •Novel form factor and proprietary technology for minimally invasive abdominal surgery, designed to be smaller and more versatile than traditional systems.
- •Potential for improved surgical access in constrained spaces.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive RBOT Stock Higher?
Near-Term (0-6 months)
- •Q1 FY2026 10-Q filing (est. late May 2026 - *if filed and contained positive news, not in current data set*): Must confirm new capital raise extending cash runway beyond Q3 2026, otherwise signals imminent liquidity crisis.
- •Successful completion of reverse stock split and Nasdaq relisting application (Q3 FY2026): Key milestone for regaining market access and attracting institutional capital; likely highly dilutive for existing shareholders.
Medium-Term (6-18 months)
- •Receipt of FDA approval/clearance for specific surgical indications (FY2027): If successful, could validate technology and attract partnership/investment interest.
- •Strategic partnership with major medical device company (FY2027-FY2028): Could provide capital, manufacturing scale, and market penetration, but highly unlikely without stronger financial health.
Long-Term (18+ months)
- •Achievement of significant commercialization and revenue generation from robotic platform (~$50M+ annualized revenue by FY2029): If clinical trials succeed and market adoption occurs, could justify re-rating.
- •Establishment of a leadership position in a niche robotic surgery segment (FY2030+): Requires substantial capital, R&D, and successful market execution over many years.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for RBOT?
- ✓
Watch for SEC filings (Form 8-K) announcing a confirmed capital raise and the amount by July 15, 2026; amount below $30M would be insufficient.
- ✓
Monitor progress and success of Nasdaq relisting efforts; any delays beyond Q3 2026 would be a negative.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Vicarious Surgical Inc Makes Money
Vicarious Surgical Inc. is developing a next-generation surgical robotics system designed to give surgeons the ability to operate internally through a single incision, mimicking human motion through miniature humanoid-like arms. The company's business model intends to generate revenue primarily through the sale of its proprietary robotic surgical systems, as well as recurring revenue from consumables and service contracts once the product achieves regulatory approval and commercialization. Currently, the company is pre-revenue, focused solely on research, development, and clinical trials for its innovative technology.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Vicarious Surgical Inc (RBOT)?
As of June 7, 2026, Vicarious Surgical Inc has a DVR Score of 1.8 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vicarious Surgical Inc?
Vicarious Surgical Inc's market capitalization is approximately $3.8M..
What is the risk level for RBOT stock?
Our analysis rates Vicarious Surgical Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Vicarious Surgical Inc's revenue growing?
Vicarious Surgical Inc has reported revenue growth of -64.6%. Revenue has been declining, which warrants closer examination.
How often is the RBOT DVR analysis updated?
Our AI-powered analysis of Vicarious Surgical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 7, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RBOT (Vicarious Surgical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.